Obtułowicz A, Barouka D, Kapusta D, et al. Early and late allergic reactions limited to adalimumab injection sites in a patient with severe plaque psoriasis. Alergologia Polska - Polish Journal of Allergology. 2025;12(3):227-231. doi:10.5114/pja.2025.153695.
APA
Obtułowicz, A., Barouka, D., Kapusta, D., Kapczyński, N., Lato, M., & Jaworek, A. et al. (2025). Early and late allergic reactions limited to adalimumab injection sites in a patient with severe plaque psoriasis. Alergologia Polska - Polish Journal of Allergology, 12(3), 227-231. https://doi.org/10.5114/pja.2025.153695
Chicago
Obtułowicz, Aleksander, Daryna Barouka, Dominika Kapusta, Norbert Kapczyński, Marta Lato, Andrzej Jaworek, and Bartosz Obtułowicz et al. 2025. "Early and late allergic reactions limited to adalimumab injection sites in a patient with severe plaque psoriasis". Alergologia Polska - Polish Journal of Allergology 12 (3): 227-231. doi:10.5114/pja.2025.153695.
Harvard
Obtułowicz, A., Barouka, D., Kapusta, D., Kapczyński, N., Lato, M., Jaworek, A., Obtułowicz, B., and Wojas-Pelc, A. (2025). Early and late allergic reactions limited to adalimumab injection sites in a patient with severe plaque psoriasis. Alergologia Polska - Polish Journal of Allergology, 12(3), pp.227-231. https://doi.org/10.5114/pja.2025.153695
MLA
Obtułowicz, Aleksander et al. "Early and late allergic reactions limited to adalimumab injection sites in a patient with severe plaque psoriasis." Alergologia Polska - Polish Journal of Allergology, vol. 12, no. 3, 2025, pp. 227-231. doi:10.5114/pja.2025.153695.
Vancouver
Obtułowicz A, Barouka D, Kapusta D, Kapczyński N, Lato M, Jaworek A et al. Early and late allergic reactions limited to adalimumab injection sites in a patient with severe plaque psoriasis. Alergologia Polska - Polish Journal of Allergology. 2025;12(3):227-231. doi:10.5114/pja.2025.153695.
Tumor necrosis factor-α (TNF-α) inhibitors, such as adalimumab, are widely used for the treatment of various inflammatory diseases, including psoriasis. Injection site reactions (ISRs) are common side effects, typically mild and self-limiting. Nevertheless, in some cases, ISRs may persist or evolve into more severe hypersensitivity reactions, requiring discontinuation or a change of the therapy. We present the case of a 40-year-old woman with plaque psoriasis who developed progressive ISRs and recall reactions during adalimumab therapy. Allergological diagnostics confirmed a delayed-type hypersensitivity reaction. Transitioning to an IL-12/IL-23 inhibitor resulted in clinical improvement, highlighting the importance of allergological testing and alternative biologic therapies.
Keywords
adalimumab, injection site reaction, recall reaction, delayed hypersensitivity, plaque psoriasis
